{
  "docId": "019dd923-5fec-763b-95d0-6c2b37f81466",
  "docSlug": "bi-9523b367be63361f",
  "documentTitle": "3T Biosciences 27-slide pitch deck to raise $40M Series A",
  "authorId": "Pitchdecks",
  "authorName": "3T Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.6,
  "pageNumber": 16,
  "pageCount": 27,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a contrast-pair framework to highlight the limitation of current therapies (~25% targetable) versus the expanded capability of the company's platform.",
  "elementsJson": [
    "action_title",
    "callout_box",
    "process_diagram"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95d0-6c2b37f81466/16",
  "deckHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.46,
        "x": 0.5,
        "y": 0.21
      },
      "kind": "callout",
      "text": "TCR based therapies can target the entire proteome expressed both intracellularly and on cell surface",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34f296ba-8950-4a5a-9293-967321286cb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.46,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "callout",
      "text": "CAR-T And Antibody based approaches can only target ~25% of proteome expressed on cell surface",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a12104a4-e8df-4dbb-9345-ad2478cb8fa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "framework",
      "text": "Comparison of therapeutic targeting capabilities",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15d5df83-eb3f-4aa5-9008-5c7c951ec1e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.7,
        "x": 0.15,
        "y": 0.32
      },
      "kind": "image",
      "text": "Diagram showing CAR-T cell, TCR-T cell, Antibody, Tumor cell, HLA, and Peptide-HLA complex interactions.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8da0d3c9-27ef-47f7-a15f-824d3a536c34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "3T-TRACE™ Discovery Platform Allows for Intracellular Targeting of Immunotherapies for Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f881f87-b529-4baa-acce-35f4d16aabcd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "af01d5d4-f69e-4eb2-885a-69be6e4c8a4d",
      "evidence": "framework/instance: Comparison of therapeutic targeting capabilities",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "contrast-pairs",
      "slug": null,
      "matchId": "cd23da79-052c-4f35-a82c-d0371d37d14c",
      "evidence": "The slide explicitly contrasts the limited scope of CAR-T/Antibodies with the expanded scope of TCR-based therapies.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}